| Q43099699 | A lung segmental model of chronic Pseudomonas infection in sheep |
| Q37972333 | Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent? |
| Q33786154 | Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections |
| Q38821019 | Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. |
| Q44512892 | Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis |
| Q41453012 | Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients |
| Q36374382 | Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis |
| Q38367260 | Clinical pharmacokinetics of inhaled antimicrobials. |
| Q27022401 | Cystic fibrosis therapeutics: the road ahead |
| Q38170953 | Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis |
| Q27004711 | Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis |
| Q40320244 | Infections in cystic fibrosis: Up-to-date |
| Q33755342 | Inhaled Antibiotic Therapy in Chronic Respiratory Diseases |
| Q26822988 | Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead |
| Q33640488 | Inhaled antibiotics for lower airway infections. |
| Q58094329 | Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis |
| Q26764900 | Inhaled antibiotics for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes |
| Q26797450 | Inhaled therapy in cystic fibrosis: agents, devices and regimens |
| Q36627996 | Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. |
| Q57688993 | Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis |
| Q90424133 | Lying in Wait: Modeling the Control of Bacterial Infections via Antibiotic-Induced Proviruses |
| Q38634682 | Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin |
| Q92542722 | Nanomedicine Approaches for the Pulmonary Treatment of Cystic Fibrosis |
| Q38128069 | Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases |
| Q36288672 | Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis |
| Q35801062 | Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease. |
| Q37678156 | Personalized therapeutics for levofloxacin: a focus on pharmacokinetic concerns |
| Q34297656 | Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients |
| Q37209004 | Progress in cystic fibrosis and the CF Therapeutics Development Network |
| Q33824149 | Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment |
| Q34375926 | State of progress in treating cystic fibrosis respiratory disease |
| Q48507010 | Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection. |
| Q83156270 | Technological and behavioral strategies to reduce treatment burden and improve adherence to inhaled antibiotics in cystic fibrosis |
| Q47730320 | The Rationale and Evidence for Use of Inhaled Antibiotics to Control Pseudomonas aeruginosa Infection in Non-cystic Fibrosis Bronchiectasis |
| Q61912424 | Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics |
| Q24186014 | Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis |
| Q57688970 | Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis |
| Q54318026 | Treatment of pseudomonas and Staphylococcus bronchopulmonary infection in patients with cystic fibrosis. |